First Manhattan CO Blueprint Medicines Corp Transaction History

First Manhattan CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $12.3 Million - $19.1 Million	271,956 Added 86.18%	587,512 $29.7 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $204,993 - $252,278	-2,175 Reduced 0.68%	315,556 $33.8 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $6.04 Million - $7.37 Million	73,000 Added 29.83%	317,731 $27.9 Million
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $117,922 - $140,764	-1,300 Reduced 0.53%	244,731 $23.8 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $10.5 Million - $14.2 Million	-114,200 Reduced 31.7%	246,031 $27.6 Million
Q3 2020 Nov 12, 2020	SELL	$66.45 - $92.7 $13.8 Million - $19.2 Million	-207,300 Reduced 36.53%	360,231 $33.4 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $17.7 Million - $24.6 Million	310,031 Added 120.4%	567,531 $44.3 Million
Q1 2020 May 06, 2020	BUY	$48.11 - $82.22 $12.4 Million - $21.2 Million	257,500 New	257,500 $15.1 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.